Relative risk of chronic health conditions among HCT survivors according to primary diagnosis, stem cell donor type, and therapeutic exposures compared with siblings
| Primary diagnosis or therapeutic exposures . | Grades 1-4 . | Grades 1-2 . | Grades 3-4 . | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall . | Autologous . | Allogeneic with chronic GVHD . | Allogeneic without chronic GVHD . | Overall . | Autologous . | Allogeneic with chronic GVHD . | Allogeneic without chronic GVHD . | Overall . | Autologous . | Allogeneic with chronic GVHD . | Allogeneic without chronic GVHD . | |
| Siblings | 1.0 | 1.0 | 1.0 | |||||||||
| All survivors | 1.81 (1.55-2.11) | 1.64 (1.39-1.94) | 2.09 (1.77-2.46) | 2.06 (1.73-2.45) | 1.86 (1.56-2.23) | 1.69 (1.39-2.05) | 2.18 (1.79-2.65) | 2.13 (1.73-2.61) | 3.52 (2.31-5.38) | 2.63 (1.65-4.18) | 4.65 (3.00-7.22) | 4.42 (2.82-6.93) |
| Primary cancer diagnosis | ||||||||||||
| SAA | 1.83 (1.43-2.35) | — | 2.12 (1.59-2.82) | 1.81 (1.24-2.66) | 1.91 (1.42-2.57) | — | 2.26 (1.57-3.26) | 1.85 (1.21-2.85) | 3.27 (1.50-7.10) | — | 4.81 (2.12-10.89) | 2.66 (0.71-9.96) |
| CML | 1.90 (1.60-2.26) | 1.31 (0.83-2.05) | 2.04 (1.70-2.46) | 1.98 (1.61-2.44) | 2.00 (1.63-2.45) | 1.29 (0.74-2.27) | 2.21 (1.76-2.77) | 2.10 (1.64-2.69) | 3.65 (2.27-5.88) | 1.80 (0.57-5.65) | 3.95 (2.38-6.55) | 3.77 (2.09-6.80) |
| AML | 1.86 (1.57-2.20) | 1.69 (1.35-2.12) | 2.15 (1.77-2.61) | 1.98 (1.58-2.48) | 1.86 (1.51-2.29) | 1.73 (1.32-2.28) | 2.10 (1.62-2.74) | 2.03 (1.54-2.66) | 4.07 (2.58-6.43) | 2.76 (1.46-5.21) | 5.59 (3.47-9.02) | 4.20 (2.32-7.61) |
| Hodgkin lymphoma | 1.55 (1.23-1.97) | 1.57 (1.23-1.99) | — | — | 1.61 (1.22-2.13) | 1.64 (1.24-2.18) | — | — | 2.17 (1.09-4.32) | 2.19 (1.08-4.44) | — | — |
| NHL | 1.79 (1.50-2.14) | 1.72 (1.43-2.07) | 2.05 (1.50-2.79) | 2.65 (1.95-3.61) | 1.87 (1.51-2.31) | 1.78 (1.43-2.22) | 1.99 (1.21-3.26) | 2.97 (2.09-4.20) | 3.28 (2.00-5.37) | 2.80 (1.66-4.72) | 5.65 (2.95-10.80) | 6.50 (2.08-20.36) |
| ALL | 2.01 (1.63-2.48) | 1.96 (1.26-3.05) | 1.98 (1.45-2.70) | 2.54 (1.95-3.31) | 2.00 (1.53-2.60) | 1.95 (1.09-3.49) | 1.97 (0.35-2.88) | 2.59 (1.80-3.72) | 4.89 (2.92-8.17) | 4.13 (1.48-11.54) | 3.91 (1.78-8.59) | 7.07 (4.07-12.29) |
| Multiple myeloma | 1.35 (0.95-1.92) | 1.08 (0.69-1.70) | — | — | 1.33 (0.84-2.09) | 0.94 (0.50-1.74) | — | — | 2.10 (0.92-4.77) | 1.79 (0.72-4.49) | — | — |
| Stem cell donor type | ||||||||||||
| Allogeneic, unrelated donor | 1.99 (1.65-2.41) | — | — | — | 2.05 (1.62-2.60) | — | — | — | 4.58 (2.76-7.59) | — | — | — |
| Allogeneic, sibling | 1.99 (1.70-2.33) | — | — | — | 2.05 (1.70-2.47) | — | — | — | 4.48 (2.92-6.89) | — | — | — |
| Autologous | 1.63 (1.38-1.92) | — | — | — | 1.68 (1.38-2.03) | — | — | — | 2.65 (1.67-4.20) | — | — | — |
| Transplantation regimen | ||||||||||||
| Chemotherapy-based regimen | 1.58 (1.31-1.90) | 1.52 (1.23-1.87) | 2.09 (1.63-2.69) | 1.60 (1.16-2.19) | 1.64 (1.32-2.03) | 1.58 (1.23-2.02) | 2.18 (1.57-3.03) | 1.72 (1.22-2.42) | 2.39 (1.42-4.03) | 2.14 (1.19-3.86) | 4.80 (2.45-9.41) | 1.15 (0.29-4.54) |
| TBI-based regimen | 1.89 (1.62-2.20) | 1.71 (1.44-2.03) | 2.09 (1.77-2.47) | 2.15 (1.80-2.56) | 1.94 (1.62-2.32) | 1.75 (1.43-2.14) | 2.18 (1.78-2.66) | 2.23 (1.81-2.75) | 3.90 (2.55-5.97) | 2.91 (1.80-4.68) | 4.63 (2.97-7.22) | 4.89 (3.13-4.63) |
| Immunosuppressive drugs for management of GVHD | ||||||||||||
| Any immunosuppression | 1.99 (1.70-2.32) | — | 2.09 (1.77-2.46) | 2.06 (1.73-2.46) | 2.05 (1.70-2.46) | — | 2.19 (1.80-2.66) | 2.12 (1.73-2.61) | 4.51 (2.95-6.89) | — | 4.63 (2.98-7.19) | 4.54 (2.90-7.12) |
| Methotrexate | 2.00 (1.71-2.34) | — | 2.08 (1.75-2.46) | 2.12 (1.78-2.53) | 2.07 (1.71-2.49) | — | 2.16 (1.76-2.65) | 2.21 (1.80-2.72) | 4.48 (2.92-6.88) | — | 4.55 (2.91-7.13) | 4.56 (2.88-7.21) |
| Cyclosporine | 1.88 (1.60-2.21) | — | 2.01 (1.70-2.39) | 1.86 (1.52-2.28) | 1.96 (1.62-2.38) | — | 2.14 (1.74-2.62) | 1.94 (1.53-2.45) | 3.56 (2.26-5.61) | — | 3.94 (2.46-6.31) | 3.15 (1.80-5.51) |
| Prednisone | 2.01 (1.70-2.36) | — | 2.10 (1.77-2.49) | 2.09 (1.72-2.54) | 2.09 (1.72-2.53) | — | 2.19 (1.78-2.70) | 2.18 (1.73-2.76) | 4.45 (2.86-6.92) | — | 4.81 (3.06-7.55) | 4.12 (2.43-6.99) |
| Primary diagnosis or therapeutic exposures . | Grades 1-4 . | Grades 1-2 . | Grades 3-4 . | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall . | Autologous . | Allogeneic with chronic GVHD . | Allogeneic without chronic GVHD . | Overall . | Autologous . | Allogeneic with chronic GVHD . | Allogeneic without chronic GVHD . | Overall . | Autologous . | Allogeneic with chronic GVHD . | Allogeneic without chronic GVHD . | |
| Siblings | 1.0 | 1.0 | 1.0 | |||||||||
| All survivors | 1.81 (1.55-2.11) | 1.64 (1.39-1.94) | 2.09 (1.77-2.46) | 2.06 (1.73-2.45) | 1.86 (1.56-2.23) | 1.69 (1.39-2.05) | 2.18 (1.79-2.65) | 2.13 (1.73-2.61) | 3.52 (2.31-5.38) | 2.63 (1.65-4.18) | 4.65 (3.00-7.22) | 4.42 (2.82-6.93) |
| Primary cancer diagnosis | ||||||||||||
| SAA | 1.83 (1.43-2.35) | — | 2.12 (1.59-2.82) | 1.81 (1.24-2.66) | 1.91 (1.42-2.57) | — | 2.26 (1.57-3.26) | 1.85 (1.21-2.85) | 3.27 (1.50-7.10) | — | 4.81 (2.12-10.89) | 2.66 (0.71-9.96) |
| CML | 1.90 (1.60-2.26) | 1.31 (0.83-2.05) | 2.04 (1.70-2.46) | 1.98 (1.61-2.44) | 2.00 (1.63-2.45) | 1.29 (0.74-2.27) | 2.21 (1.76-2.77) | 2.10 (1.64-2.69) | 3.65 (2.27-5.88) | 1.80 (0.57-5.65) | 3.95 (2.38-6.55) | 3.77 (2.09-6.80) |
| AML | 1.86 (1.57-2.20) | 1.69 (1.35-2.12) | 2.15 (1.77-2.61) | 1.98 (1.58-2.48) | 1.86 (1.51-2.29) | 1.73 (1.32-2.28) | 2.10 (1.62-2.74) | 2.03 (1.54-2.66) | 4.07 (2.58-6.43) | 2.76 (1.46-5.21) | 5.59 (3.47-9.02) | 4.20 (2.32-7.61) |
| Hodgkin lymphoma | 1.55 (1.23-1.97) | 1.57 (1.23-1.99) | — | — | 1.61 (1.22-2.13) | 1.64 (1.24-2.18) | — | — | 2.17 (1.09-4.32) | 2.19 (1.08-4.44) | — | — |
| NHL | 1.79 (1.50-2.14) | 1.72 (1.43-2.07) | 2.05 (1.50-2.79) | 2.65 (1.95-3.61) | 1.87 (1.51-2.31) | 1.78 (1.43-2.22) | 1.99 (1.21-3.26) | 2.97 (2.09-4.20) | 3.28 (2.00-5.37) | 2.80 (1.66-4.72) | 5.65 (2.95-10.80) | 6.50 (2.08-20.36) |
| ALL | 2.01 (1.63-2.48) | 1.96 (1.26-3.05) | 1.98 (1.45-2.70) | 2.54 (1.95-3.31) | 2.00 (1.53-2.60) | 1.95 (1.09-3.49) | 1.97 (0.35-2.88) | 2.59 (1.80-3.72) | 4.89 (2.92-8.17) | 4.13 (1.48-11.54) | 3.91 (1.78-8.59) | 7.07 (4.07-12.29) |
| Multiple myeloma | 1.35 (0.95-1.92) | 1.08 (0.69-1.70) | — | — | 1.33 (0.84-2.09) | 0.94 (0.50-1.74) | — | — | 2.10 (0.92-4.77) | 1.79 (0.72-4.49) | — | — |
| Stem cell donor type | ||||||||||||
| Allogeneic, unrelated donor | 1.99 (1.65-2.41) | — | — | — | 2.05 (1.62-2.60) | — | — | — | 4.58 (2.76-7.59) | — | — | — |
| Allogeneic, sibling | 1.99 (1.70-2.33) | — | — | — | 2.05 (1.70-2.47) | — | — | — | 4.48 (2.92-6.89) | — | — | — |
| Autologous | 1.63 (1.38-1.92) | — | — | — | 1.68 (1.38-2.03) | — | — | — | 2.65 (1.67-4.20) | — | — | — |
| Transplantation regimen | ||||||||||||
| Chemotherapy-based regimen | 1.58 (1.31-1.90) | 1.52 (1.23-1.87) | 2.09 (1.63-2.69) | 1.60 (1.16-2.19) | 1.64 (1.32-2.03) | 1.58 (1.23-2.02) | 2.18 (1.57-3.03) | 1.72 (1.22-2.42) | 2.39 (1.42-4.03) | 2.14 (1.19-3.86) | 4.80 (2.45-9.41) | 1.15 (0.29-4.54) |
| TBI-based regimen | 1.89 (1.62-2.20) | 1.71 (1.44-2.03) | 2.09 (1.77-2.47) | 2.15 (1.80-2.56) | 1.94 (1.62-2.32) | 1.75 (1.43-2.14) | 2.18 (1.78-2.66) | 2.23 (1.81-2.75) | 3.90 (2.55-5.97) | 2.91 (1.80-4.68) | 4.63 (2.97-7.22) | 4.89 (3.13-4.63) |
| Immunosuppressive drugs for management of GVHD | ||||||||||||
| Any immunosuppression | 1.99 (1.70-2.32) | — | 2.09 (1.77-2.46) | 2.06 (1.73-2.46) | 2.05 (1.70-2.46) | — | 2.19 (1.80-2.66) | 2.12 (1.73-2.61) | 4.51 (2.95-6.89) | — | 4.63 (2.98-7.19) | 4.54 (2.90-7.12) |
| Methotrexate | 2.00 (1.71-2.34) | — | 2.08 (1.75-2.46) | 2.12 (1.78-2.53) | 2.07 (1.71-2.49) | — | 2.16 (1.76-2.65) | 2.21 (1.80-2.72) | 4.48 (2.92-6.88) | — | 4.55 (2.91-7.13) | 4.56 (2.88-7.21) |
| Cyclosporine | 1.88 (1.60-2.21) | — | 2.01 (1.70-2.39) | 1.86 (1.52-2.28) | 1.96 (1.62-2.38) | — | 2.14 (1.74-2.62) | 1.94 (1.53-2.45) | 3.56 (2.26-5.61) | — | 3.94 (2.46-6.31) | 3.15 (1.80-5.51) |
| Prednisone | 2.01 (1.70-2.36) | — | 2.10 (1.77-2.49) | 2.09 (1.72-2.54) | 2.09 (1.72-2.53) | — | 2.19 (1.78-2.70) | 2.18 (1.73-2.76) | 4.45 (2.86-6.92) | — | 4.81 (3.06-7.55) | 4.12 (2.43-6.99) |
Each row represents an individual multivariate regression model, adjusted for sex, age in years at study participation, race (non-Hispanic white vs others), education, household income, and health insurance status.
— indicates not applicable.